PD0325901 drug
Evidence from:
primary |
all sources
Related entities (1)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| PD0325901 | targets | MAPK | — | 1 |
Mentioned in (6)
Papers in which this entity is mentioned.
- Genetic compensation triggered by mutant mRNA degradation. (2019)
- Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. (2018)
- Disconnect between alcohol-induced alterations in chromatin structure and gene transcription in a mouse embryonic stem cell model of exposure. (2017)
- Establishment of human iPSC-based models for the study and targeting of glioma initiating cells. (2016)
- Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. (2013)
- The genomic landscape of hypodiploid acute lymphoblastic leukemia. (2013)
Merged raw entities (1)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| pd0325901 | drug | 6 | 11 |